We compared the immunotherapy response rates between ARID1A-mutated and ARID1A-wildtype cancers (melanoma) in the Allen cohort and Hugo cohort and found that ARID1A-mutated cancers had higher response rates than ARID1A-wildtype cancers (42.86% versus 25.81% in Allen cohort, and 100% versus 51.43% in Hugo cohort) (Figure 4B). This evidence concerns the gene ARID1A and cancer.